Business Wire

Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...
Nasdaq

Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes

Sana Biotechnology reports six-month results from a first-in-human study demonstrating safe pancreatic islet cell transplantation for type 1 diabetes without immunosuppression. Sana Biotechnology ...
Nasdaq

Sana Biotechnology Reports Promising Results from First-in-Human Study Demonstrating Hypoimmune Technology for Transplanting Islet Cells in Type 1 Diabetes Without ...

Sana's first-in-human study shows HIP technology allows islet cells to avoid immune rejection and produce insulin without immunosuppression. Reliance on initial results: The press release heavily ...